Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Update

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRXGet Free Report) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 5,960,000 shares, a growth of 5.9% from the December 31st total of 5,630,000 shares. Based on an average daily volume of 1,480,000 shares, the days-to-cover ratio is presently 4.0 days. Currently, 6.5% of the shares of the stock are sold short.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 40,000 shares of Catalyst Pharmaceuticals stock in a transaction on Tuesday, December 5th. The shares were sold at an average price of $14.24, for a total value of $569,600.00. Following the completion of the transaction, the insider now directly owns 647,457 shares of the company’s stock, valued at approximately $9,219,787.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director David S. Tierney sold 50,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $13.32, for a total transaction of $666,000.00. Following the transaction, the director now owns 333,541 shares of the company’s stock, valued at approximately $4,442,766.12. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Steve Miller sold 40,000 shares of the stock in a transaction on Tuesday, December 5th. The shares were sold at an average price of $14.24, for a total value of $569,600.00. Following the sale, the insider now owns 647,457 shares in the company, valued at approximately $9,219,787.68. The disclosure for this sale can be found here. Insiders sold 190,000 shares of company stock worth $2,632,400 over the last 90 days. 12.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CPRX. Advisory Services Network LLC raised its holdings in Catalyst Pharmaceuticals by 260.2% in the 1st quarter. Advisory Services Network LLC now owns 1,801 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 1,301 shares during the period. VisionPoint Advisory Group LLC acquired a new stake in Catalyst Pharmaceuticals during the second quarter worth about $43,000. FMR LLC raised its position in shares of Catalyst Pharmaceuticals by 24.2% during the 2nd quarter. FMR LLC now owns 4,218 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 822 shares during the period. Covestor Ltd raised its position in Catalyst Pharmaceuticals by 768.0% in the first quarter. Covestor Ltd now owns 4,878 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 4,316 shares during the period. Finally, Nisa Investment Advisors LLC raised its holdings in Catalyst Pharmaceuticals by 306.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 3,829 shares during the period. 77.27% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on CPRX shares. TheStreet lowered shares of Catalyst Pharmaceuticals from a “b” rating to a “c+” rating in a research report on Thursday, November 9th. StockNews.com started coverage on shares of Catalyst Pharmaceuticals in a report on Thursday, October 5th. They issued a “hold” rating for the company. Finally, Oppenheimer initiated coverage on Catalyst Pharmaceuticals in a research report on Thursday, December 21st. They issued an “outperform” rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.80.

Check Out Our Latest Research Report on CPRX

Catalyst Pharmaceuticals Stock Up 2.2 %

Shares of Catalyst Pharmaceuticals stock opened at $14.77 on Wednesday. The company has a 50 day moving average price of $14.97 and a 200 day moving average price of $13.85. The firm has a market capitalization of $1.74 billion, a P/E ratio of 28.40 and a beta of 1.01. Catalyst Pharmaceuticals has a 52 week low of $11.09 and a 52 week high of $18.22.

Catalyst Pharmaceuticals (NASDAQ:CPRXGet Free Report) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.26). Catalyst Pharmaceuticals had a return on equity of 19.32% and a net margin of 17.81%. The firm had revenue of $102.69 million during the quarter, compared to analysts’ expectations of $100.17 million. As a group, research analysts anticipate that Catalyst Pharmaceuticals will post 1.81 earnings per share for the current fiscal year.

About Catalyst Pharmaceuticals

(Get Free Report)

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

Further Reading

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.